OBJECTIVE: To determine whether incident AIDS-defining Kaposi sarcoma or Pneumocystis jiroveci pneumonia (PJP) is associated with combination antiretroviral therapy (cART) initiation. DESIGN: Compare risk for Kaposi sarcoma and PJP by time on cART and CD4 reconstitution. METHODS: : In the FHDH-ANRS CO4 cohort (N = 66 369), Kaposi sarcoma (N = 1811) and PJP (N = 1718) incidence rates were computed by demographic and HIV strata. Crude and adjusted relative risk (RR) with 95% confidence intervals (CIs) following cART initiation were calculated by Poisson regression with untreated patients during 1996-2009 as reference. CD4 cell counts were compared by Wilcoxon rank sum tests. RESULTS: The risk of Kaposi sarcoma was very high during months 1-3 on cART (N = 160, RRCrude 3.94, 95% CI 3.26-4.76), which was incompletely attenuated by adjustment for demographics and contemporaneous CD4 cell count (RRAdj 1.25, 95% CI 1.02-1.53). Corresponding PJP risk was minimally elevated (N = 84, RRCrude 1.80, 95% CI 1.42-2.30) and markedly reduced with adjustment on the same variables and PJP prophylaxis (RRAdj 0.52, CI 0.41-0.67). HIV load had no added effect. Median CD4 cell count at cART initiation was much lower in patients with incident Kaposi sarcoma (82 cells/μl) or PJP (61 cells/μl) within 3 months than in those who did not develop these conditions (>250 cells/μl). Notably, median CD4 cell count change was +44 cells/μl per month with incident Kaposi sarcoma within 3 months of cART initiation versus 0 cells/μl per month with incident PJP (P = 0.0003). CONCLUSION: Failure of CD4 cell count reconstitution during months 1-3 on cART fully accounted for incident PJP. In contrast, there were 1.6 additional Kaposi sarcoma cases per 1000 person-years during months 1-3 on cART, suggesting that immune reconstitution may contribute to the risk for AIDS-defining Kaposi sarcoma.
OBJECTIVE: To determine whether incident AIDS-defining Kaposi sarcoma or Pneumocystis jiroveci pneumonia (PJP) is associated with combination antiretroviral therapy (cART) initiation. DESIGN: Compare risk for Kaposi sarcoma and PJP by time on cART and CD4 reconstitution. METHODS: : In the FHDH-ANRS CO4 cohort (N = 66 369), Kaposi sarcoma (N = 1811) and PJP (N = 1718) incidence rates were computed by demographic and HIV strata. Crude and adjusted relative risk (RR) with 95% confidence intervals (CIs) following cART initiation were calculated by Poisson regression with untreated patients during 1996-2009 as reference. CD4 cell counts were compared by Wilcoxon rank sum tests. RESULTS: The risk of Kaposi sarcoma was very high during months 1-3 on cART (N = 160, RRCrude 3.94, 95% CI 3.26-4.76), which was incompletely attenuated by adjustment for demographics and contemporaneous CD4 cell count (RRAdj 1.25, 95% CI 1.02-1.53). Corresponding PJP risk was minimally elevated (N = 84, RRCrude 1.80, 95% CI 1.42-2.30) and markedly reduced with adjustment on the same variables and PJP prophylaxis (RRAdj 0.52, CI 0.41-0.67). HIV load had no added effect. Median CD4 cell count at cART initiation was much lower in patients with incident Kaposi sarcoma (82 cells/μl) or PJP (61 cells/μl) within 3 months than in those who did not develop these conditions (>250 cells/μl). Notably, median CD4 cell count change was +44 cells/μl per month with incident Kaposi sarcoma within 3 months of cART initiation versus 0 cells/μl per month with incident PJP (P = 0.0003). CONCLUSION: Failure of CD4 cell count reconstitution during months 1-3 on cART fully accounted for incident PJP. In contrast, there were 1.6 additional Kaposi sarcoma cases per 1000 person-years during months 1-3 on cART, suggesting that immune reconstitution may contribute to the risk for AIDS-defining Kaposi sarcoma.
Authors: Samuel A Shelburne; Richard J Hamill; Maria C Rodriguez-Barradas; Stephen B Greenberg; Robert L Atmar; Daniel W Musher; Joseph C Gathe; Fehmida Visnegarwala; Barbara W Trautner Journal: Medicine (Baltimore) Date: 2002-05 Impact factor: 1.889
Authors: Yolanda D Mahnke; Jamieson H Greenwald; Rebecca DerSimonian; Gregg Roby; Lis R V Antonelli; Alan Sher; Mario Roederer; Irini Sereti Journal: Blood Date: 2012-01-04 Impact factor: 22.113
Authors: Eric A Engels; Robert J Biggar; Vickie A Marshall; Michael A Walters; Christine J Gamache; Denise Whitby; James J Goedert Journal: AIDS Date: 2003-08-15 Impact factor: 4.177
Authors: Kara K Bennett; Victor G DeGruttola; Ian C Marschner; Diane V Havlir; Douglas D Richman Journal: J Acquir Immune Defic Syndr Date: 2002-09-01 Impact factor: 3.731
Authors: Mohamed A Eltom; Ahmedin Jemal; Sam M Mbulaiteye; Susan S Devesa; Robert J Biggar Journal: J Natl Cancer Inst Date: 2002-08-21 Impact factor: 13.506
Authors: Julia Bohlius; Fabio Valeri; Mhairi Maskew; Hans Prozesky; Daniela Garone; Mazvita Sengayi; Matthew P Fox; Mary-Ann Davies; Matthias Egger Journal: Int J Cancer Date: 2014-05-02 Impact factor: 7.396
Authors: Elaine Chang; Srikar R Mapakshi; Pamela Mbang; Nader Kim El-Mallawany; Jennifer R Kramer; Donna L White; Elizabeth Y Chiao Journal: J Acquir Immune Defic Syndr Date: 2018-10-01 Impact factor: 3.771
Authors: Elizabeth L Yanik; Christina A Clarke; Jon J Snyder; Ruth M Pfeiffer; Eric A Engels Journal: J Am Soc Nephrol Date: 2015-11-12 Impact factor: 14.978